AI-Powered Blood Test Detects Early Signs of Liver Disease
A new artificial intelligence (AI)-driven liquid biopsy can detect early liver fibrosis and cirrhosis – often before symptoms appear – by analyzing patterns in cell-free DNA (cfDNA) fragments circulating in the blood. The technology, developed by researchers at the Johns Hopkins Kimmel Cancer Center, may also reveal signals of broader chronic disease burden.
How the AI Blood Test Works
Unlike traditional liver disease tests that often miss early-stage damage, this innovative approach examines how DNA fragments break apart and where they appear across the genome. This method, known as fragmentome technology, analyzes genome-wide DNA fragmentation patterns rather than searching for specific gene mutations. By examining both the size and distribution of these fragments, including repetitive DNA regions, the AI system identifies patterns linked to disease.
Breakthrough in Chronic Disease Detection
Published in Science Translational Medicine on March 4, 2026, this research marks the first time fragmentome technology has been systematically applied to detecting chronic diseases beyond cancer. Previously, this type of DNA fragmentation analysis was primarily used in cancer research. The study involved analyzing cfDNA samples from 1,576 individuals with liver disease and other medical conditions. Machine learning algorithms processed the data to identify fragmentation patterns associated with disease, creating a highly sensitive classification system.
Why DNA Fragment Analysis is Different
Traditional liquid biopsies often focus on identifying specific cancer-related gene mutations. The fragmentome approach, however, takes a broader view, analyzing how DNA is fragmented and distributed. This makes it applicable to a wider range of conditions, including those that can increase cancer risk. According to Akshaya Annapragada, an M.D./Ph.D. Student involved in the research, “The fact that we are not looking for individual mutations is what makes this study so powerful. We are analyzing the entire fragmentome, which contains a tremendous amount of information about a person’s physiologic state.”
Potential Impact on Liver Disease Management
Approximately 100 million people in the United States have liver conditions that increase their risk of cirrhosis and liver cancer 1. Current blood-based tests for fibrosis often lack sensitivity, particularly in the early stages. The AI-driven liquid biopsy offers a potentially more accurate and earlier detection method, allowing for earlier intervention and potentially reversing liver fibrosis before it progresses to cirrhosis or cancer.
Beyond Liver Disease: A Comorbidity Index
Researchers also developed a fragmentation comorbidity index, analyzing data from 570 individuals with suspected serious illness. This index accurately distinguished between individuals with high and low Charlson Comorbidity Index scores – a measure of overall health risk – and even proved more specific than traditional inflammatory markers in some cases. Fragmentome signatures were also linked to poorer clinical outcomes.
Future Directions
While the current assay for liver fibrosis is still a prototype, the research team is working to refine and validate it for clinical leverage. They are also exploring fragmentome signatures associated with other chronic illnesses, including cardiovascular, inflammatory, and neurodegenerative disorders. The study was funded in part by the National Institutes of Health 1, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and several other organizations.
Key Takeaways
- An AI-powered liquid biopsy can detect early signs of liver fibrosis and cirrhosis.
- The technology analyzes patterns in cell-free DNA fragmentation, offering a broader view than traditional mutation-based tests.
- Early detection could lead to more effective treatment and potentially prevent liver cancer.
- Researchers are exploring the potential of this technology to detect other chronic diseases.
Sources: